Source / episode info

• **Episode:**198
• **Title:**Divine Intervention Episode 198 – Clutch Hypertensive Integrations.
• **Published:**2020-01-04
• Source:Episode page

One-liner

This episode provides high-yield integration of anti-hypertensive agents, emphasizing specific drug choices for comorbidities such as pregnancy, heart failure, BPH, and renal impairment, while detailing critical contraindications like ACE inhibitor use in DIMA or bilateral renal artery stenosis.

High-yield summary

• Pregnancy: First-line options include Hydralazine, Labetalol, Alpha-methyldopa, and Methyldopa. Never use ACE inhibitors or ARBs due to fetal renal risk.
• Heart Failure (HF): Agents proven to improve survival are Beta-blockers (Metoprolol, Carvedilol, Bisoprolol), ACE Inhibitors/ARBs (Lisinopril, Telmisartan), Mineralocorticoid Receptor Antagonists (Spironolactone, Eplerenone), and Nitrates.
• Renal Impairment: In HTN with CKD or diabetes, ACE inhibitors or ARBs are preferred agents due to their ability to decrease intraglomerular hypertension.
• Specific Comorbidities: For BPH/HTN, use an Alpha-1 blocker (e.g., Tamsulosin). For HTN + Osteoporosis, Thiazides are beneficial because they help raise serum calcium levels.
• Contraindications: Avoid ACE inhibitors and ARBs in patients with Hereditary Dystonia of the Aortic Arch (DIMA) or Bilateral Renal Artery Stenosis due to risk of acute kidney injury.

Learning objectives

• Select appropriate anti-hypertensive agents based on the patient's specific comorbidities (e.g., pregnancy, renal failure, BPH).
• Understand the mechanisms and clinical implications of major drug classes (ACEi, ARBs, CCBs, Alpha/Beta blockers).
• Recognize high-risk contraindications for anti-hypertensives in conditions like DIMA or bilateral renal artery stenosis.
• Identify specific drugs used to manage secondary complications of HTN, such as nephrogenic DI or pheochromocytoma crisis.

Board exam buzzwords